Manufacture and sale of inflammatory bowel disease treatmentsManufacture and sale of pharmaceuticals
§04
Related companies
0 COMPANIES
—
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
60 EVENTS
Establishment of Zeria Pharmaceutical Research Institute Ltd. (Chuo-ku, Tokyo, capital of 3 million yen)
Release of the pharmaceutical "Chondroitin"
Release of joint pain and lower back pain treatment "Chondroitin ZS Tablets"
Release of "Hepalyse Tablets"
Changed trade name to Zeria Shinyaku Kogyo Co., Ltd.
New construction of Saitama Factory in Kounan-cho, Osato-gun, Saitama Prefecture (now Kumagaya City)
Release of "New Hepalyse", a tonic and liver hydrolysate formulation
New construction of Central Research Institute in Kounan-cho, Osato-gun, Saitama Prefecture (now Kumagaya City)
Release of absorbable topical hemostatic agent "Abiten", introduced and developed from Alcon Inc. in the United States
Release of plant-based laxative "WithOne"
New construction of Tsukuba Factory in Katsura, Ushiku City, Ibaraki Prefecture
Introduction from Eli Lilly & Co. in the United States, jointly developed with Eli Lilly Japan Co., Ltd., of the gastric ulcer treatment "Asinon Capsules 150"
Release of "Answer 20 Injection", a drug to suppress leukopenia caused by radiation therapy
Joint development with Chugai Pharmaceutical Co., Ltd., of the non-steroidal analgesic and anti-inflammatory drug "Peon Tablets 80"
Joint development with Nissan Chemical Industries, Ltd., of the antihypertensive drug "Randel Tablets 10 & 20"
Release of the zinc-containing gastric ulcer treatment "Promac Granules 15%"
Release of "New Hepalyse Plus", a tonic and liver hydrolysate formulation
Listed on the Tokyo Stock Exchange Second Section on December 22. Completely renewed symbol mark and company logo
Commissioning logistics operations to Itochu Corporation and its affiliates Super Rex to activate a new logistics system
Listed on the First Section of the Tokyo Stock Exchange on March 1
Contract with Swiss company Tilott's Pharma for the development, manufacturing, and sale of the inflammatory bowel disease treatment drug "Asacol" in Japan
Launch of "New Hepalyse Drink," a tonic and liver hydrolysate-containing beverage
Chondroitin group sales surpass 5 billion yen
Launch of zinc-containing gastric ulcer treatment "Promac D Tablets 75"
Expansion of Tsukuba Factory Building No. 2
Launch of "Bisclear Tablets," a colon cleansing agent before colonoscopy
Launch of "Asinon Tablets 75mg and 150mg" for gastritis and ulcer treatment
Start of TV commercials for "Chondroitin ZS Tablets"
Acquisition of all shares of Ionaine International and making it a subsidiary
Acquisition of all shares of Swiss company Tilott's Pharma and making it a subsidiary
Launch of "Asacol Tablets 400mg" for ulcerative colitis treatment
Start of TV commercials for "New Hepalyse Drink"
Acquisition of shares of Danish ZPD (formerly Biofock Esbia) and making it a subsidiary
Launch of "Hepalyse W," a beverage for convenience stores
Launch of "New Wizone," a plant-based laxative
Start of TV commercials for "New Wizone"
Launch of "Hosribon," a low-phosphorus treatment drug
Launch of "Acofide Tablets 100mg" for functional dyspepsia treatment
Launch of convenience store-oriented soft drink "Heparlyze W Hyper"
Launch of premenstrual syndrome treatment drug "PreFemin"
Launch of convenience store-oriented carbonated beverage "Heparlyze W Sparkling"
Tylott's Pharma acquired rights for "Entocort" excluding the US from AstraZeneca for worldwide rights
Acquired 49% of shares of Pharmaceutical Joint Stock Company of February 3rd (now a consolidated subsidiary) and made it a subsidiary
Launch of nourishing tonic and liver hydrolysate containing "Heparlyze Plus II"
Launch of convenience store-oriented soft drink "Heparlyze W Premium"
Heparlyze group sales exceeded 10 billion yen
Additional acquisition of shares of Pharmaceutical Joint Stock Company of February 3rd (now a consolidated subsidiary), increasing ownership to 77.89%
Launch of nourishing mini drink "Heparlyze King Plus" and "Heparlyze King EX"
Launch of Crohn's disease treatment drug "Zentacort Capsule 3mg"
Launch of convenience store-oriented soft drink "Heparlyze W Premium Extreme"
Acquired all shares of Kensou Pharmaceutical (formerly Nihon Suisei Pharmaceutical) and made it a subsidiary
Launch of iron deficiency anemia treatment drug "Fainject Intravenous Injection 500mg"
Succession of manufacturing and sales rights for "Deficliar Tablets" for Clostridioides difficile infection from Astellas Pharma Europe Ltd. to Tillotts Pharma AG (now a consolidated subsidiary) for Europe, Middle East, Africa, and the Commonwealth of Independent States
Launch of drug "Belfemin" to improve mild venous reflux disorder and leg swelling
Launch of drug "Corpermin" for irritable bowel syndrome (IBS) improvement
Transition from the First Section to the Prime Market of the Tokyo Stock Exchange due to review of market segments
Succession of manufacturing and sales approval for "Dafclear Tablets 200mg" for infectious enteritis caused by Clostridioides difficile from Astellas Pharma to the company
Launch of convenience store-oriented soft drink "Heparlyze W Shine"
Launch of the hyperkalemia treatment drug "Viltasa Suspension Pack 8.4g"